FDAnews Drug Daily Bulletin

PROSTRAKAN HALVES LOSSES AND WINS UK RIGHTS FOR PROSTATE TREATMENT

March 27, 2006
A A

Borders-based biotech company ProStrakan halved its losses in 2005 despite increased spending linked to its rapid growth through expansion in recent years. The firm, which floated on the London market in June of last year, separately announced its acquisition of the UK rights forTabphyn for an undisclosed sum.
Black Enterprise